Wertli, Maria Monika; Flury, Julian S; Streit, Sven; Limacher, Andreas; Schuler, Vanessa; Ferrante, Asha-Naima; Rimensberger, Caroline; Haschke, Manuel (2021). Efficacy of metamizole versus ibuprofen and a short educational intervention versus standard care in acute and subacute low back pain: a study protocol of a randomised, multicentre, factorial trial (EMISI trial). BMJ open, 11(10), e048531. BMJ Publishing Group 10.1136/bmjopen-2020-048531
|
Text
2021-10-13_Wertli.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (711kB) | Preview |
INTRODUCTION
Low back pain (LBP) is among the top three most common diseases worldwide, resulting in a life with pain-related disability. To date, no study has assessed the efficacy of metamizole (dipyrone), a non-opioid analgesic and antipyretic prodrug compared with the conventional non-steroidal anti-inflammatory drug ibuprofen, in patients with an acute LBP episode. Further, it is unclear, whether a short educational intervention is superior to usual care alone.
OBJECTIVES
The objective of this study is to assess first, whether metamizole is non-inferior to ibuprofen in a new episode of acute or subacute LBP. Second, we aim to assess whether a short educational intervention including evidence-based patient information on the nature of LBP is superior to usual care alone.
METHODS AND ANALYSIS
An investigator-initiated multicentre, randomised, double blind trial using a factorial design will be performed. A total of 120 participants with a new episode of LBP will be recruited from GP practices, outpatient clinics and from emergency departments, and randomised into four different treatment groups: ibuprofen alone, ibuprofen and short intervention, metamizole alone, metamizole and short intervention. The primary endpoint for the medical treatment will be change in pain assessed on an 11-point Numeric Rating Scale after 14 days. The primary outcome for the short intervention will be change in the Core Outcome Measures Index assessed after 42 days.
ETHICS, DISSEMINATION AND FUNDING
This study has been approved by the responsible Ethics Board (Ethikkommission Bern/2018-01986) and the Swiss Agency for Therapeutic Products (Swissmedic/2019DR4002). Results will be published in open access policy peer-reviewed journals. The study is funded by the Swiss National Science Foundation (grant number 32 003B-179346).
TRIAL REGISTRATION NUMBER
NCT04111315.
Actions (login required)
 |
Edit item |